Myocardial injury following an ischemic insult continues to be a challenge in terms of effectively managing or repairing the damage as well as preventing development of chronic heart failure (HF). A real urgency exists to delineate molecular pathological mechanisms for potential new therapeutic targets. Over the last 15 years we have identified a key role for G protein-coupled receptor (GPCR) kinase-2 (GRK2) in the pathophysiology of injured or stressed myocardium. Inhibition of GRK2 activity in small animal models of HF can improve cardiac function and morphology. This has primarily been done using a peptide inhibitor of GRK2, the bARKct, however, recent studies using cardiomyocyte-specific GRK2 knockout (KO) mice have provided similar beneficial results in ischemic HF. Canonically, GRK2 phosphorylates agonist-activated GPCRs, such as b- adrenergic receptors (bARs) in the heart, triggering the process of desensitization. GRK-mediated phosphorylation causes b-arrestin binding to the receptor, which blocks further G protein signaling. Interestingly, b-arrestins (b-arrestin1 and b-arrestin2 are in the heart) can also initiate intracellular signaling pathways after interacting with desensitized receptors through kinase scaffolding, which is independent of G protein signaling. A goal in this proposal is to discover novel GRK2 dependent mechanisms involved in myocardial ischemic injury and repair processes. We now have data that suggests that beneficial GRK2- dependent mechanisms in the injured heart go beyond bAR signaling and control of contractility and include myocyte survival. In this proposal we will test whether acute and/or chronic cardioprotection supported by lower GRK2 expression and/or activity might be due to events beyond cellular contractile signaling including regeneration targeted through either myocytes or stem/progenitor cells. This proposal will also begin the novel investigation into the role of b-arrestins, acting downstream of GRK activity, in myocardial ischemic injury and repair. This will be done using b-arrestin1 and b-arrestin2 KO mice and cultured myocytes and cardiac stem/progenitor cells. In fact, we have preliminary data that demonstrates b-arrestins play a critical role in bone marrow-derived cardiac stem/progenitor cell growth and function. Our Central Hypothesis is that GRK2 activity and subsequent b-arrestin function play novel roles downstream of GPCR desensitization that are critically involved in the heart's response to ischemic injury including potential repair and regeneration. Studies in this Project will employ both in vivo and in vitro techniques addressing cardiac repair through new myocyte formation and also GRK2-related mechanisms involved in the proliferation and function of bone-marrow- derived and resident cardiac stem cells.

Public Health Relevance

Elucidating novel roles for GRK2 (and b-arrestins acting downstream in a GRK-dependent manner) in the heart beyond its effect on b-adrenergic receptor signaling and contractile function will lead to a broader understanding of novel aspects of GRKs, which may be especially critical in the heart's response to ischemic injury and heart failure development. This includes a role for GRK2 in cardiomyocyte survival and proliferation, which could mediate novel cardiac repair through regeneration. Since levels and activity of GRK2 are elevated in injured and compromised myocardium, mechanistic elucidation of these novel aspects of GRK2 function will lead to a broader understanding of the pathogenesis of myocardial dysfunction, which may provide targets for new therapeutic strategies to combat ischemic injury and subsequent heart failure. Finally, b-arrestins are being appreciated more for their novel signaling functions and their role in cardiac injury and repair has been under-studied, and this proposal will shed innovative light on this area of cardiac biology.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Adhikari, Bishow B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Temple University
Schools of Medicine
United States
Zip Code
Hullmann, Jonathan E; Grisanti, Laurel A; Makarewich, Catherine A et al. (2014) GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ Res 115:976-85
Miller, Barbara A; Hoffman, Nicholas E; Merali, Salim et al. (2014) TRPM2 channels protect against cardiac ischemia-reperfusion injury: role of mitochondria. J Biol Chem 289:7615-29
Scimia, Maria C; Gumpert, Anna M; Koch, Walter J (2014) Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 14:183-95
Wang, JuFang; Song, Jianliang; Gao, Erhe et al. (2014) Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 306:H1066-77
Kim, Il-Man; Wang, Yongchao; Park, Kyoung-Mi et al. (2014) *-arrestin1-biased *1-adrenergic receptor signaling regulates microRNA processing. Circ Res 114:833-44
Woodall, Meryl C; Ciccarelli, Michele; Woodall, Benjamin P et al. (2014) G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism. Circ Res 114:1661-70
Bathgate-Siryk, Ashley; Dabul, Samalia; Pandya, Krunal et al. (2014) Negative impact of *-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension 63:404-12
Scimia, Maria Cecilia; Blass, Benjamin E; Koch, Walter J (2014) Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy. Expert Rev Cardiovasc Ther 12:733-41
Khan, Mohsin; Mohsin, Sadia; Toko, Haruhiro et al. (2014) Cardiac progenitor cells engineered with *ARKct have enhanced *-adrenergic tolerance. Mol Ther 22:178-85
Cheung, Joseph Y; Zhang, Xue-Qian; Song, Jianliang et al. (2013) Coordinated regulation of cardiac Na(+)/Ca (2+) exchanger and Na (+)-K (+)-ATPase by phospholemman (FXYD1). Adv Exp Med Biol 961:175-90

Showing the most recent 10 out of 33 publications